Detalhe da pesquisa
1.
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Haematologica
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654660
2.
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience.
Br J Cancer
; 129(7): 1126-1133, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37542108
3.
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Haematologica
; 108(1): 34-41, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678031
4.
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood
; 136(7): 823-830, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32496541
5.
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Haematologica
; 106(12): 3100-3106, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34047178
6.
Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient.
Clin Infect Dis
; 73(11): 2144-2145, 2021 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34009286
7.
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
J Cancer Res Clin Oncol
; 149(8): 4611-4621, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36167894
8.
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Trials
; 22(1): 765, 2021 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34732236